Diabetes

Educational resources

eLearning module index image

The importance of reducing cardiovascular risk in patients with type 2 diabetes

Promotional material from the Boehringer Ingelheim and Lilly Alliance

This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed. This eLearning module is intended for healthcare professionals.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
PC-GB-105238  September 2021

Trajenta animation updated index image

Prescribing a dipeptidyl peptidase-4 inhibitor in adults with type 2 diabetes and comorbidities

Commissioned by Boehringer Ingelheim Limited

This animation has been commissioned and funded by Boehringer Ingelheim Limited and developed in partnership with Guidelines in Practice.
View Trajenta (linagliptin) adverse event reporting and prescribing information for Great Britain or Northern Ireland
PC-GB-105090 Date of preparation: October 2021

Trajenta webinar index

Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care

Commissioned by Boehringer Ingelheim Limited

This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse events reporting information for:
Great Britain 
Northern Ireland
PC-GB-103485 | July 2021

Index image

Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes

Supported by an educational grant from Sanofi Ltd

This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd

Steglatro FDG inxed image

Steglatro®▼ (Ertugliflozin)

Commissioned by MSD UK Ltd

This formulary decision guide was developed from content provided by MSD UK Ltd in a format developed by Guidelines in Practice.
Prescribing Information (Great Britain) & (Northern Ireland), and Adverse Event Reporting Information
GB-STE-00433 | June 2021